Tildrakizumab For PsA

Abstract

In a previous supplement published in March 2021, we discussed the pivotal data for the interleukin (IL)-23 p19 inhibitor, tildrakizumab, for use in plaque psoriasis. The reSURFACE-1 and reSURFACE-2 clinical trial program demonstrated the durable efficacy and safety of tildrakizumab in the moderate-to-severe plaque psoriasis population. We have also seen 5-year efficacy and safety data confirming the durability of response along with no new safety concerns having arisen in the long term.